-
Mashup Score: 28Efficacy of ruxolitinib in the treatment of relapsed/refractory large granular lymphocytic leukaemia - 19 hour(s) ago
An official journal of the British Society for Haematology, the British Journal of Haematology offers high visibility for clinical, basic and translational research.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 11
VJHemOnc is excited to share an exclusive case study exploring the current approach to the diagnosis and classification of follicular lymphoma.
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 55
An official journal of the British Society for Haematology, the British Journal of Haematology offers high visibility for clinical, basic and translational research.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 53
Anti-CD30 CAR T-cell infusion as consolidation after BEAM and autologous HSCT is safe, with low rates of toxicity and encouraging preliminary activity in patients with Hodgkin lymphoma at high risk of relapse, highlighting the need for larger studies to confirm these findings.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 57
Combination of sintilimab with P-GEMOX seems to be an active and safe first-line regimen for patients with advanced ENKTL.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 9
VJHemOnc is excited to share an exclusive case study exploring the current approach to the diagnosis and classification of follicular lymphoma.
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1The value of anti-CD30 CAR T cells in Hodgkin lymphoma - 16 day(s) ago
The use of chimeric antigen receptor (CAR) T cells in haematological malignancies is becoming increasingly widespread, with several authorised drugs and many patients benefiting from their efficacy and manageable tolerance in the short and medium term.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 52
Anti-CD30 CAR T-cell infusion as consolidation after BEAM and autologous HSCT is safe, with low rates of toxicity and encouraging preliminary activity in patients with Hodgkin lymphoma at high risk of relapse, highlighting the need for larger studies to confirm these findings.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 53
Combination of sintilimab with P-GEMOX seems to be an active and safe first-line regimen for patients with advanced ENKTL.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 52
Anti-CD30 CAR T-cell infusion as consolidation after BEAM and autologous HSCT is safe, with low rates of toxicity and encouraging preliminary activity in patients with Hodgkin lymphoma at high risk of relapse, highlighting the need for larger studies to confirm these findings.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet
Marchand et al - ruxolitinib for relapsed T-LGL. 21 pts, 86% ORR, 1y EFS of 57%. Interesting but data from Alison Moskowitz group suggests stat mutation can predict responders and this will be key. #lymsm https://t.co/To2HAWe8Gw